Rafaèle Elisabeth Tordjman
Fondateur chez Women Innovating Together In Healthcare
Provenance du réseau au premier degré de Rafaèle Elisabeth Tordjman
Entité | Type d'entité | Industrie | |
---|---|---|---|
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.
28
| Private Company | Investment Managers | 28 |
Public Company | Pharmaceuticals: Major | 25 | |
Public Company | Pharmaceuticals: Major | 20 | |
19
| Public Company | Pharmaceuticals: Major | 19 |
Subsidiary | Pharmaceuticals: Major | 17 | |
14
| Public Company | Miscellaneous Commercial Services | 14 |
Alentis Therapeutics AG
Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.
9
| Holding Company | Pharmaceuticals: Major | 9 |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.
5
| Holding Company | Biotechnology | 5 |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France.
4
| Holding Company | Biotechnology | 4 |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.
1
| Holding Company | Biotechnology | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Rafaèle Elisabeth Tordjman via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
University of Copenhagen | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
IPSEN | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Comptroller/Controller/Auditor Corporate Officer/Principal | |
VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Director of Finance/CFO Chairman Director of Finance/CFO Director of Finance/CFO | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Secretary Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Stanford University | College/University | Undergraduate Degree Doctorate Degree Masters Business Admin | |
ALK-ABELLÓ A/S | Biotechnology | Chief Tech/Sci/R&D Officer Director of Finance/CFO Corporate Officer/Principal | |
INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member Director/Board Member | |
NTG NORDIC TRANSPORT GROUP A/S | Trucking | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
École des Hautes Études Commerciales de Paris | College/University | Undergraduate Degree Masters Business Admin Graduate Degree | |
AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman Director of Finance/CFO | |
The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Masters Business Admin Masters Business Admin | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Director/Board Member Founder | |
BOLT BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
PIXIUM VISION | Medical Specialties | Founder Director/Board Member Director/Board Member | |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor Corporate Officer/Principal | |
Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree | |
KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Founder Corporate Officer/Principal Corporate Officer/Principal | |
Yale University | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Chairman Director/Board Member | |
SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal Investor Relations Contact | |
Panmira Pharmaceuticals LLC
Panmira Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Panmira Pharmaceuticals LLC provides drug development programs. It develops pharmaceutical products for inflammatory diseases. The company was founded in September 2011 and is headquartered in San Diego, CA. | Pharmaceuticals: Other | Director/Board Member Chairman | |
University of Zurich | College/University | Doctorate Degree Doctorate Degree | |
National Venture Capital Association
National Venture Capital Association Miscellaneous Commercial ServicesCommercial Services National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
NextWave Pharmaceuticals, Inc.
NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Ipsen International GmbH
Ipsen International GmbH Industrial MachineryProducer Manufacturing Ipsen International GmbH manufactures and distributes furnaces and plant systems. Its products include sealed quench furnaces; chamber and multi-purpose chamber furnaces; horizontal and vertical furnaces; EcoFire system; HydroNit Sensor; HybridCarb; and EndoSave system. The firm also provides software processes such as Carb-o-Prof 4.0, AutoMag, Vacu-Prof, and Conti-Control. The company was founded by Harold Ipsen in 1957 and is headquartered in Kleve, Germany. | Industrial Machinery | Corporate Officer/Principal Public Communications Contact | |
CESSATECH A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
PricewaterhouseCoopers (Denmark)
PricewaterhouseCoopers (Denmark) Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., PricewaterhouseCoopers (Denmark) is a company based in Hellerup, Denmark. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Therachon SAS
Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Director/Board Member Chief Executive Officer | |
University of Pavia | College/University | Doctorate Degree Undergraduate Degree | |
BPIFrance Investissement SAS
BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Investment Managers | Private Equity Investor General Counsel | |
GENKYOTEX SA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Brainever SAS
Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member |
Statistiques
Internationale
Etats-Unis | 15 |
France | 12 |
Danemark | 10 |
Suisse | 10 |
Royaume-Uni | 4 |
Sectorielle
Health Technology | 32 |
Consumer Services | 11 |
Commercial Services | 5 |
Finance | 4 |
Transportation | 2 |
Opérationnelle
Director/Board Member | 806 |
Corporate Officer/Principal | 232 |
Independent Dir/Board Member | 195 |
Chairman | 158 |
Chief Executive Officer | 81 |
Relations les plus connectées
Insiders | |
---|---|
Peter Hutt | 69 |
James Healy | 50 |
Ed Mathers Mathers | 47 |
Andrew Schwab | 45 |
Heath Lukatch | 43 |
Jonathan Silverstein | 42 |
Bradley Bolzon | 41 |
Elaine Jones | 37 |
Bernard Gilly | 32 |
Albert Cha | 30 |
Mette Agger | 30 |
Catherine Moukheibir | 29 |
Torbjørn Bjerke | 27 |
Chahra Khaoua Epouse Louafi | 26 |
Graziano Seghezzi | 26 |
- Bourse
- Insiders
- Rafaèle Elisabeth Tordjman
- Connexions Sociétés